Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Krampera, Mauro  [Clear All Filters]
2014
Di Trapani M, Bassi G, Fontana E, Giacomello L, Pozzobon M, Guillot PV, De Coppi P, Krampera M. Immune regulatory properties of CD117pos amniotic fluid stem cells vary according to gestational age. Stem Cells Dev. 2014.
Mercuri A, Cannata E, Perbellini O, Cugno C, Balter R, Zaccaron A, Tridello G, Pizzolo G, De Bortoli M, Krampera M, et al. Immunophenotypic Analysis of Hematopoiesis in Patients suffering from Shwachman-Bodian-Diamond Syndrome. Eur J Haematol. 2014.
Zhao W, Phinney DG, Bonnet D, Dominici M, Krampera M. Mesenchymal stem cell biodistribution, migration, and homing in vivo. Stem Cells Int. 2014;2014:292109.
2015
Zanchetta E, Guidi E, Giustina GDella, Sorgato M, Krampera M, Bassi G, Di Liddo R, Lucchetta G, Conconi MTeresa, Brusatin G. Injection Moulded Polymeric Micropatterns for Bone Regeneration Study. ACS Appl Mater Interfaces. 2015.
Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2015.
2019
Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
2020
Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, et al. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
2021
Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021;28(10):1708-1725.
Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021.
2022
Scambi I, Peroni D, Nodari A, Merigo F, Benati D, Boschi F, Mannucci S, Frontini A, Visonà S, Sbarbati A, et al. The transcriptional profile of adipose-derived stromal cells (ASC) mirrors the whitening of adipose tissue with age. Eur J Cell Biol. 2022;101(2):151206.
Bazzoni R, Tanasi I, Turazzi N, Krampera M. Update on the role and utility of extracellular vesicles in hematological malignancies. Stem Cells. 2022.
2023
Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, et al. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Viswanathan S, Le Blanc K, Ciccocioppo R, Dagher G, Filiano AJ, Galipeau J, Krampera M, Krieger L, Lalu MM, Nolta J, et al. An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone marrow-MSCs and umbilical cord tissue-derived MSCs for . Cytotherapy. 2023.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EMaria, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
2024
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.